Literature DB >> 1414218

Myasthenia gravis in Hong Kong Chinese. 1. Epidemiology and adult disease.

Y L Yu1, B R Hawkins, M S Ip, V Wong, E Woo.   

Abstract

A territory-wide study of myasthenia gravis (MG) was conducted in Hong Kong. Two hundred and sixty-two Chinese patients (159 adult and 103 paediatric onset) were identified, corresponding to a point prevalence and period prevalence of 53.5 and 62.2 per million respectively, and an average annual incidence of 4.0 per million population. Nine patients died, 7 from MG, giving a case fatality rate of 0.027. Female predominance was present in the whole group of patients (female to male ratio 1.6:1) and in those with adult disease (ratio 2.1:1), but not in those with onset in childhood (ration 1.1:1). Onset of disease was most common in the first 3 decades of life, and became less common in subsequent decades. Juvenile onset MG occurred in 39.3% of patients and restricted ocular MG in 47.9%. Familial occurrence was found in 5 patients. In the 159 adult onset patients, ocular disease was most common (32.7%), followed by mild generalised (29.6%), moderately severe generalised (24.5%), fulminating (11.9%) and late severe disease (1.3%). The mean age of onset of symptoms was 36.7 years. The symptomatology was similar to that of Caucasoid populations. Autoimmune thyroid disease was the commonest associated disease, and the incidence of thymoma among thymic abnormalities was high at 38%.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1414218     DOI: 10.1111/j.1600-0404.1992.tb05050.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  15 in total

1.  Nationwide population-based epidemiological study of myasthenia gravis in taiwan.

Authors:  Chien-Hsu Lai; Hung-Fu Tseng
Journal:  Neuroepidemiology       Date:  2010-06-03       Impact factor: 3.282

2.  Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years.

Authors:  X Huang; W B Liu; L N Men; H Y Feng; Y Li; C M Luo; L Qiu
Journal:  Neurol Sci       Date:  2012-07-18       Impact factor: 3.307

3.  Both binding and blocking antibodies correlate with disease severity in myasthenia gravis.

Authors:  Sa-Yoon Kang; Jung-Hwan Oh; Sook Keun Song; Jung Seok Lee; Jay Chol Choi; Ji-Hoon Kang
Journal:  Neurol Sci       Date:  2015-05-12       Impact factor: 3.307

Review 4.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

5.  Epidemiology of seropositive myasthenia gravis in Greece.

Authors:  K Poulas; E Tsibri; A Kokla; D Papanastasiou; T Tsouloufis; M Marinou; P Tsantili; T Papapetropoulos; S J Tzartos
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-09       Impact factor: 10.154

6.  Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England.

Authors:  N P Robertson; J Deans; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-10       Impact factor: 10.154

Review 7.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

8.  A population based epidemiological study on myasthenia gravis in Estonia.

Authors:  M Oöpik; A-E Kaasik; J Jakobsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

9.  Incidence and Prevalence of Myasthenia Gravis in Korea: A Population-Based Study Using the National Health Insurance Claims Database.

Authors:  Su Yeon Park; Jin Yong Lee; Nam Gu Lim; Yoon Ho Hong
Journal:  J Clin Neurol       Date:  2016-05-10       Impact factor: 3.077

10.  Incidence of thymoma in myasthenia gravis: a systematic review.

Authors:  Zhi-Feng Mao; Xue-An Mo; Chao Qin; Yong-Rong Lai; Maree L Hackett
Journal:  J Clin Neurol       Date:  2012-09-27       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.